Cambridge Innovation Capital
Dr Michael Anstey is a Partner specializing in life science investments.
Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group√¢¬Ä¬ôs (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early stage life science businesses.
Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.
Education, Personal, and Fellowship
Mike graduated with a 1st Class Honors degree in Biology from Queen's University, Canada, and earned his DPhil in Zoology from Oxford University, where he was the Hope Scholar.
Michael served his fellowship at Cambridge Innovation Capital under the mentorship of Victor Christou. He is a member of Class 22.